195 related articles for article (PubMed ID: 31661150)
21. Management of Glioblastoma, Present and Future.
Oberheim Bush NA; Hervey-Jumper SL; Berger MS
World Neurosurg; 2019 Nov; 131():328-338. PubMed ID: 31658576
[TBL] [Abstract][Full Text] [Related]
22. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for Uveal Melanoma.
Breazzano MP; Milam RW; Batson SA; Johnson DB; Daniels AB
Int Ophthalmol Clin; 2017; 57(1):29-39. PubMed ID: 27898611
[No Abstract] [Full Text] [Related]
24. American Association of Cancer Research Showcases Immunotherapy Advances.
Brower V
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
[No Abstract] [Full Text] [Related]
25. [Towards a holistic vision of cancer].
Solary É; Laplane L
Med Sci (Paris); 2016 Apr; 32(4):315-6. PubMed ID: 27137681
[No Abstract] [Full Text] [Related]
26. Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT).
Smoragiewicz M; Adjei AA; Calvo E; Tabernero J; Marabelle A; Massard C; Tang J; de Vries EGE; Douillard JY; Seymour L;
Clin Cancer Res; 2020 Jun; 26(11):2461-2465. PubMed ID: 32086344
[TBL] [Abstract][Full Text] [Related]
27. Decade in review-targeted therapy: successes, toxicities and challenges in solid tumours.
Neal JW; Sledge GW
Nat Rev Clin Oncol; 2014 Nov; 11(11):627-8. PubMed ID: 25286974
[No Abstract] [Full Text] [Related]
28. Managing Hodgkin lymphoma without chemotherapy: a novel, yet 'welcomed', challenge.
Kourie HR; Tabchi S; Kattan J
Future Oncol; 2016 Jun; 12(12):1435-7. PubMed ID: 27117227
[No Abstract] [Full Text] [Related]
29. Editorial (Thematic Issue: Clinical Advances in Immuno-oncology - Progress Towards Selective Cure).
Liu X; Belani CP
Curr Mol Pharmacol; 2016; 9(3):182. PubMed ID: 26177639
[No Abstract] [Full Text] [Related]
30. Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy.
Cully M
Nat Rev Drug Discov; 2015 Jun; 14(6):374-5. PubMed ID: 26027531
[No Abstract] [Full Text] [Related]
31. [New therapeutic strategies in non-Hodgkin lymphomas and Hodgkin lymphoma].
Rossi C; Bastie JN
Rev Med Interne; 2019 Apr; 40(4):246-254. PubMed ID: 29801709
[TBL] [Abstract][Full Text] [Related]
32. Emerging therapeutics in refractory renal cell carcinoma.
Koshkin VS; Rini BI
Expert Opin Pharmacother; 2016 Jun; 17(9):1225-32. PubMed ID: 27112171
[TBL] [Abstract][Full Text] [Related]
33. The RACE to accelerate drug development for children with cancer.
Pearson ADJ; Karres D; Reaman G; DuBois SG; Knox L; Scobie N; Vassal G
Lancet Child Adolesc Health; 2020 Oct; 4(10):714-716. PubMed ID: 32822672
[No Abstract] [Full Text] [Related]
34. Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.
Swaika A; Hammond WA; Joseph RW
Mol Immunol; 2015 Oct; 67(2 Pt A):4-17. PubMed ID: 25749122
[TBL] [Abstract][Full Text] [Related]
35. Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.
Long KB; Collier AI; Beatty GL
Mol Immunol; 2019 Jun; 110():3-12. PubMed ID: 29273393
[TBL] [Abstract][Full Text] [Related]
36. [Combinations of chemotherapy or radiotherapy with checkpoint inhibitors].
Ghiringhelli F
Biol Aujourdhui; 2018; 212(3-4):77-79. PubMed ID: 30973135
[TBL] [Abstract][Full Text] [Related]
37. An Update on the Use of Immunotherapy in the Treatment of Lymphoma.
Marron TU; Kalac M; Brody J
Curr Hematol Malig Rep; 2017 Aug; 12(4):282-289. PubMed ID: 28735365
[TBL] [Abstract][Full Text] [Related]
38. Some statistical considerations in the clinical development of cancer immunotherapies.
Huang B
Pharm Stat; 2018 Feb; 17(1):49-60. PubMed ID: 29098766
[TBL] [Abstract][Full Text] [Related]
39. [Cancer immunotherapy: Rational and recent breakthroughs].
Granier C; Karaki S; Roussel H; Badoual C; Tran T; Anson M; Fabre E; Oudard S; Tartour E
Rev Med Interne; 2016 Oct; 37(10):694-700. PubMed ID: 27370898
[TBL] [Abstract][Full Text] [Related]
40. Integrating first-line treatment options into clinical practice: what's new in advanced melanoma?
Dummer R; Schadendorf D; Ascierto PA; Larkin J; Lebbé C; Hauschild A
Melanoma Res; 2015 Dec; 25(6):461-9. PubMed ID: 26426764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
